REFERENCES
1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO
guideline for the definition, classification, diagnosis and management
of urticaria. Allergy. 2018;73(7):1393-1414.
2. Weller K, Groffik A, Church MK, et al. Development and validation of
the Urticaria Control Test: a patient-reported outcome instrument for
assessing urticaria control. J Allergy Clin Immunol.2014;133(5):1365-1372, 1372.e1361-1366.
3. Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M.
Clinical Measures of Chronic Urticaria. Immunol Allergy Clin North
Am. 2017;37(1):35-49.
4. Park Y-M, Oh M-S, Kwon J-W. Predicting inadequate treatment response
in children with chronic spontaneous urticaria. Pediatr Allergy
Immunol. 2020;31(8):946-953.
5. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic
urticaria in children: a clinical guideline. Ital J Pediatr.2019;45(1):101-101.
6. Maurer M, Giménez-Arnau A, Ensina LF, Chu C-Y, Jaumont X, Tassinari
P. Chronic urticaria treatment patterns and changes in quality of life:
AWARE study 2-year results. World Allergy Organ J.2020;13(9):100460-100460.
7. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index
as an outcome measure for urticaria-related quality of life. Ann
Allergy Asthma Immunol. 2004;93(2):142-146.
8. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality
Index (CDLQI): initial validation and practical use. Br J
Dermatol. 1995;132(6):942-949.
9. Holme SA, Man I, Sharpe JL, Dykes PJ, Lewis-Jones MS, Finlay AY. The
Children’s Dermatology Life Quality Index: validation of the cartoon
version. Br J Dermatol. 2003;148(2):285-290.
10. Salek MS, Jung S, Brincat-Ruffini LA, et al. Clinical experience and
psychometric properties of the Children’s Dermatology Life Quality Index
(CDLQI), 1995-2012. Br J Dermatol. 2013;169(4):734-759.
11. Oztürkcan S, Ermertcan AT, Eser E, Sahin MT. Cross validation of the
Turkish version of dermatology life quality index. Int J
Dermatol. 2006;45(11):1300-1307.
12. Beattie* PE, Lewis-Jones MS. A comparative study of impairment of
quality of life in children with skin disease and children with other
chronic childhood diseases. Br J Dermatol. 2006;155(1):145-151.
13. Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the
treatment of chronic spontaneous urticaria in children aged 2–11 years.Pediatr Allergy Immunol. 2016;27(1):55-61.
14. Weller K, Groffik A, Church MK, et al. Development and validation of
the Urticaria Control Test: A patient-reported outcome instrument for
assessing urticaria control. J Allergy Clin Immunol.2014;133(5):1365-1372.e1366.
15. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international
EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition,
classification, diagnosis, and management of urticaria. Allergy.2021;n/a(n/a).
16. Miles LM, Gabrielli S, Le M, et al. Clinical Characteristics,
Management, and Natural History of Chronic Inducible Urticaria in a
Pediatric Cohort. Int Arch Allergy Immunol. 2021;182(8):757-764.
17. Kocatürk E, Kızıltaç U, Can P, et al. Validation of the Turkish
version of the Urticaria Control Test: Correlation with other tools and
comparison between spontaneous and inducible chronic urticaria.World Allergy Organ J. 2019;12(1):100009.
18. Bonett DG, Wright TA. Sample size requirements for estimating
Pearson, Kendall and Spearman correlations. Psychometrika.2000;65(1):23-28.
19. Schober P, Boer C, Schwarte LA. Correlation Coefficients:
Appropriate Use and Interpretation. Anesth Analg. 2018;126(5).
20. Waters A, Sandhu D, Beattie P, Ezughah F, Lewis-Jones S. Severity
stratification of Children’s Dermatology Life Quality Index (CDLQI)
scores: PA-8. Br J Dermatol. 2010;163.
21. Bruins FM, Bronckers IMGJ, Cai R, et al. Treatment persistence in
paediatric and adolescent patients with psoriasis followed into young
adulthood. From topical to systemic treatment: a prospective,
longitudinal, observational cohort study of 448 patients*. Br J
Dermatol. 2021;184(3):464-472.
22. Youden WJ. Index for rating diagnostic tests. Cancer.1950;3(1):32-35.
23. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic
Regression. Wiley; 2013.
24. Finlay AY, Basra MKA. DLQI and CDLQI scores should not be combined.Br J Dermatol. 2012;167(2):453-454.
25. Itakura A, Tani Y, Kaneko N, Hide M. Impact of chronic urticaria on
quality of life and work in Japan: Results of a real-world study.J Dermatol. 2018;45(8):963-970.
26. Kulthanan K, Chularojanamontri L, Tuchinda P, Rujitharanawong C,
Maurer M, Weller K. Validity, reliability and interpretability of the
Thai version of the urticaria control test (UCT). Health Qual Life
Outcomes. 2016;14(1):61.
27. U. S. Department of Health Human Services, F. D. A. Center for Drug
Evaluation Research, U. S. Department of Health Human Services, F. D. A.
Center for Biologics Evaluation Research, U. S. Department of Health
Human Services, F. D. A. Center for Devices Radiological Health.
Guidance for industry: patient-reported outcome measures: use in medical
product development to support labeling claims: draft guidance.Health Qual Life Outcomes. 2006;4(1):79.
28. Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity
Score—Validity, Reliability, and Responsiveness. J Allergy Clin
Immunol Pract. 2018;6(4):1185-1190.e1181.